

Javier Alonso Nieto Guevara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3867138/publications.pdf>

Version: 2024-02-01

9
papers

76
citations

1478505

6
h-index

1588992

8
g-index

11
all docs

11
docs citations

11
times ranked

64
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. <i>Expert Review of Vaccines</i> , 2022, 21, 201-214.	4.4	17
2	Ten years of experience with the pneumococcal non-typeable <i>Haemophilus influenzae</i> protein D-conjugate vaccine (Synflorix) in children. <i>Expert Review of Vaccines</i> , 2020, 19, 247-265.	4.4	16
3	CIRCULATING CLONAL COMPLEXES AND SEQUENCE TYPES OF <i>STREPTOCOCCUS PNEUMONIAE</i> SEROTYPE 19A WORLDWIDE: THE IMPORTANCE OF MULTIDRUG RESISTANCE: A SYSTEMATIC LITERATURE REVIEW. <i>Expert Review of Vaccines</i> , 2021, 20, 45-57.	4.4	10
4	Interchangeability between pneumococcal conjugate vaccines for pediatric use: a systematic literature review. <i>Expert Review of Vaccines</i> , 2020, 19, 1011-1022.	4.4	8
5	Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-18.	3.3	7
6	Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	3.3	6
7	Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4667-4672.	3.3	4
8	Response to: Pneumococcal conjugate vaccines in Latin America: are PCV10 and PCV13 similar in terms of protection against serotype 19A?. <i>Expert Review of Vaccines</i> , 2018, 17, 283-284.	4.4	2
9	Reply to Emergence of <i>Streptococcus pneumoniae</i> serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10™. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2307-2308.	3.3	0